Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.40    -1.00 (-1.51%)
Bid:
64.90
Ask:
65.20
Spread: 0.30 (0.462%)
Market Cap: £577.76m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Pre-closed-period update

13 Jan 2022 07:00

RNS Number : 2824Y
IP Group PLC
13 January 2022
 

FOR RELEASE ON

13 January 2022

 

IP Group plc - pre-closed-period update

 

Highlights

· FY21 profit anticipated to be above £425m (FY20: profit £185.4m)

· FY21 Hard NAV per share* anticipated to be above 165p (FY20: 125.3p), a return of at least 31%

· Net cash and deposits of £276m at 31 Dec 2021 (FY20: £203m)

· Portfolio companies well-funded having raised over £2bn in 2021 (FY20: £1.1bn)

 

IP Group plc (LSE: IPO) ("IP Group", "the Company" or "the Group"), the developer of intellectual property-based businesses, issues an unaudited pre-close update ahead of its results for the 12 months to 31 December 2021.

 

In financial terms, 2021 was another highly successful year with a large number of significant transactions including the flotation of Oxford Nanopore Technologies plc on the London Stock Exchange and the sales of Inivata Ltd and WaveOptics Ltd.

 

Consequently, the Directors currently expect the Group's profit for 2021 to be above £425m (FY20: profit £185.4m). Hard NAV per share is anticipated to be above 165 pence, a return of at least 31%.

 

The Group is in a strong financial position with net cash and deposits of £276m at year-end. The Group's portfolio is well funded with portfolio companies having raised over £2bn in 2021 (FY20: £1.1bn). This, combined with the exciting prospects and investment opportunities within the portfolio, gives us confidence for 2022.

 

IP Group expects to announce its 2021 results in mid-March.

 

Notes

 

*'Hard NAV per share' reflects net assets/total equity less goodwill and intangibles divided by outstanding shares.

 

The share price of Oxford Nanopore Technologies plc was 697 pence at 31 December 2021.

 

This update is based on unaudited information and is subject to change following the completion of the Group's usual full year-end reporting process and annual audit.

 

This announcement may contain forward looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors which could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors relating to the financial or commercial prospects or performance of individual companies within the Group's portfolio.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDBGDBCSBDGDD
Date   Source Headline
17th Jan 20257:00 amRNSTransaction in Own Shares
15th Jan 20255:34 pmRNSTransaction in Own Shares
15th Jan 20253:21 pmRNSForm 8.3 - Tissue Regenix Group plc
15th Jan 20257:00 amRNSTransaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
10th Jan 20256:02 pmRNSTransaction in Own Shares
10th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20257:00 amRNSShare buyback programme update
8th Jan 20257:00 amRNSTransaction in Own Shares
6th Jan 20255:43 pmRNSTransaction in Own Shares
31st Dec 20247:00 amRNSTotal Voting Rights
20th Dec 20245:09 pmRNSTransaction in Own Shares
20th Dec 20241:46 pmRNSForm 8.3 - Intelligent Ultrasound Group plc
20th Dec 20247:00 amRNS-RTwo life sciences companies receive cash offers
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20241:10 pmRNS£119m initial cash after sale of Featurespace
18th Dec 20246:26 pmRNSTransaction in Own Shares
18th Dec 20247:00 amRNSTransaction in Own Shares
16th Dec 20244:55 pmRNSTransaction in Own Shares
13th Dec 20245:59 pmRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
12th Dec 20247:00 amRNSAGM post-meeting shareholder engagement update
12th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
9th Dec 20242:44 pmRNSHolding(s) in Company
9th Dec 202412:00 pmRNSHolding(s) in Company
9th Dec 20247:00 amRNSSecondary sale of minority holdings in portfolio
6th Dec 20245:13 pmRNSTransaction in Own Shares
6th Dec 20241:57 pmRNSForm 8.3 - Tissue Regenix Group plc
6th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20245:18 pmRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20241:35 pmRNSHolding(s) in Company
2nd Dec 20247:01 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20246:16 pmRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
25th Nov 20246:09 pmRNSTransaction in Own Shares
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
21st Nov 20247:00 amRNSTransaction in Own Shares
20th Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20245:59 pmRNSTransaction in Own Shares
15th Nov 20248:45 amRNSForm 8.3 - Tissue Regenix Group plc
15th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20245:10 pmRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.